Literature DB >> 18660858

The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia.

Herbert Lepor, Norman E Lepor, Lawrence A Hill, Richard G Trohman.   

Abstract

The QT interval is the electrocardiographic manifestation of ventricular depolarization and repolarization. Drug-induced long QT syndrome is characterized by acquired, corrected QT (QTc) interval prolongation that is associated with increased risk of torsade de pointes. Every physician must recognize if the drugs he or she prescribes prolongs the QTc interval, especially if the drug is prescribed for a chronic condition in older patients who are on polypharmacy. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia has allowed the development of drugs that are easier to administer and better tolerated. Because alpha-blockers generally have equivalent efficacy, this class of drugs is typically differentiated by safety and side effects. Studies suggest that alpha-blockers may vary in regard to their effect on the QT interval, and, therefore, on their predisposition to cause potentially life-threatening ventricular arrhythmias.

Entities:  

Keywords:  Alpha-blockers; Benign prostatic hyperplasia; Drug-induced long QT syndrome; Torsade de pointes

Year:  2008        PMID: 18660858      PMCID: PMC2483321     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  24 in total

1.  Drug-induced torsade de pointes.

Authors:  R G Trohman; J Sahu
Journal:  Circulation       Date:  1999-04-27       Impact factor: 29.690

Review 2.  Drug induced QT prolongation and torsades de pointes.

Authors:  Yee Guan Yap; A John Camm
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

Review 3.  Detection and reporting of drug-induced proarrhythmias: room for improvement.

Authors:  Börje Darpö
Journal:  Europace       Date:  2007-09       Impact factor: 5.214

4.  Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.

Authors:  Ping Yang; Hideaki Kanki; Benoit Drolet; Tao Yang; Jian Wei; Prakash C Viswanathan; Stefan H Hohnloser; Wataru Shimizu; Peter J Schwartz; Marshall Stanton; Katherine T Murray; Kris Norris; Alfred L George; Dan M Roden
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

5.  Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias.

Authors:  C Napolitano; P J Schwartz; A M Brown; E Ronchetti; L Bianchi; A Pinnavaia; G Acquaro; S G Priori
Journal:  J Cardiovasc Electrophysiol       Date:  2000-06

Review 6.  Prescribing amiodarone: an evidence-based review of clinical indications.

Authors:  Patricia Vassallo; Richard G Trohman
Journal:  JAMA       Date:  2007-09-19       Impact factor: 56.272

7.  Alfuzosin delays cardiac repolarization by a novel mechanism.

Authors:  Antonio E Lacerda; Yuri A Kuryshev; Yuan Chen; Muthukrishnan Renganathan; Heather Eng; Sanjay J Danthi; James W Kramer; Tianen Yang; Arthur M Brown
Journal:  J Pharmacol Exp Ther       Date:  2007-11-06       Impact factor: 4.030

Review 8.  Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.

Authors:  David Zeltser; Dan Justo; Amir Halkin; Vitaly Prokhorov; Karin Heller; Sami Viskin
Journal:  Medicine (Baltimore)       Date:  2003-07       Impact factor: 1.889

9.  Alpha blockers for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2007

10.  Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.

Authors:  J T Hii; D G Wyse; A M Gillis; H J Duff; M A Solylo; L B Mitchell
Journal:  Circulation       Date:  1992-11       Impact factor: 29.690

View more
  3 in total

1.  Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2009

Review 2.  Lower urinary tract symptoms in men.

Authors:  John M Hollingsworth; Timothy J Wilt
Journal:  BMJ       Date:  2014-08-14

3.  A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.

Authors:  R Manjunatha; H P Pundarikaksha; H R Madhusudhana; J Amarkumar; B K Hanumantharaju
Journal:  Indian J Pharmacol       Date:  2016 Mar-Apr       Impact factor: 1.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.